Low-dose Chemotherapy Keeps Cancer Under Control

Rather than try to wipe out cancer with powerful doses of chemotherapy, researchers say an experimental approach using lower amounts of medication may work better to keep tumors under control.

The study was done on mice with breast cancer, according to the report in Science Translational Medicine, and is part of a growing movement in oncology to explore alternatives to high-dose chemo and its often toxic side effects.

“Our results suggest that this adaptive therapeutic strategy… can result in prolonged progression-free survival in breast cancer,”

Some researchers question the use of standard chemotherapy because it rarely wipes out cancer entirely, and leaves behind drug-resistant cells that can take over and lead to an explosion in tumor growth.

Klement et al., Science Translational Medicine

The new approach delivers continuous low-dose chemotherapy, in this case paclitaxel, that stabilizes the tumor by maintaining a small population of drug-sensitive tumor cells to suppress the growth of resistant cells, said the study.

Adaptive Therapy

Standard doses of paclitaxel in mice shrunk breast tumors, but these tumors grew back once the treatment ended.

“Another treatment regimen that skips doses whenever the tumor shrunk also inevitably resulted in tumor progression,” the authors wrote in the study.

“In contrast, adaptive therapy consisting of high initial drug doses followed by progressively lower doses as the tumor responded was more effective in controlling tumor growth than either standard therapy or dose skipping.”

The study found that 60 to 80 percent of the mice treated by adaptive therapy could be “weaned off the drug completely without relapsing for an extended period of time.”

More research is needed before the approach can be recommended for use in people. However, the research offers a very good possibility for future therapies, Giannoula Klement, of the Tufts University School of Medicine in Boston, wrote in an accompanying editorial:

“More and more oncologists are engaging some version of this approach.”